Lipocine Inc.
LPCN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001535955
No open-market purchases or sales by Lipocine Inc. insiders were filed in the last 90 days; 36 institutions reported holding it in 13F filings for Q2 2026, worth $7.63M in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Lipocine Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- −2 vs. Q3 2023
- Shares held
- 483.9K
- −16.0K (−3.2%) vs. Q3 2023
- Total value
- $1.35M
- −$139.3K (−9.4%) vs. Q3 2023
- New holders
- 1
- 6 more added
- Sold out
- 3
- 4 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LPCN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 36 | $7.63M |
| Q1 2026 | 47 | $24.9M |
| Q4 2025 | 26 | $13.1M |
| Q3 2025 | 22 | $1.51M |
| Q2 2025 | 18 | $1.67M |
| Q1 2025 | 19 | $1.65M |
| Q4 2024 | 17 | $2.38M |
| Q3 2024 | 18 | $2.44M |
| Q2 2024 | 19 | $4.38M |
| Q1 2024 | 18 | $2.46M |
| Q4 2023 | 19 | $1.35M |
| Q3 2023 | 21 | $1.48M |
| Q2 2023 | 24 | $2.40M |
| Q1 2023 | 45 | $3.17M |
| Q4 2022 | 49 | $4.16M |
| Q3 2022 | 46 | $4.85M |
| Q2 2022 | 46 | $9.54M |
| Q1 2022 | 44 | $16.2M |
| Q4 2021 | 39 | $10.5M |
| Q3 2021 | 38 | $10.0M |
| Q2 2021 | 33 | $12.8M |
| Q1 2021 | 42 | $12.4M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Lipocine Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 221,459 | $617.9K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 74,846 | $208.8K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 56,601 | $156.2K | 0.00% | +31,272+123.5% | Added |
| Geode Capital Management, LLC | 48,854 | $134.9K | 0.00% | 00.0% | Unchanged |
| Two Sigma Advisers, LP | 26,222 | $73.2K | 0.00% | −30,700−53.9% | Reduced |
| Renaissance Technologies LLC | 18,797 | $52.0K | 0.00% | +3,200+20.5% | Added |
| State Street Corp | 18,626 | $51.4K | 0.00% | 00.0% | Unchanged |
| Wealth Effects LLC | 14,639 | $40.8K | 0.02% | −4,122−22.0% | Reduced |
| Tower Research Capital LLC (TRC) | 2,238 | $6.24K | 0.00% | +1,984+781.1% | Added |
| Morgan Stanley | 722 | $2.01K | 0.00% | 00.0% | Unchanged |
| Caldwell Sutter Capital, Inc. | 471 | $1.31K | 0.00% | 00.0% | Unchanged |
| FMR LLC | 90 | $248 | 0.00% | +31+52.5% | Added |
| Advisor Group Holdings, Inc. | 68 | $189 | 0.00% | 00.0% | Unchanged |
| Tidemark, LLC | 59 | $165 | 0.00% | +59 | New |
| Group One Trading, L.P. | 52 | $144 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 41 | $114 | 0.00% | +2+5.1% | Added |
| JPMorgan Chase & Co | 9 | $25 | 0.00% | −174−95.1% | Reduced |
| Bank of America Corp | 6 | $16 | 0.00% | −53−89.8% | Reduced |
| Royal Bank of Canada | 91 | $0 | 0.00% | +14+18.2% | Added |
| Kestra Advisory Services, LLC | 0 | $0 | 0.00% | −16,703−100.0% | Sold out |
| Cutler Group LP | 0 | $0 | 0.00% | −765−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −42−100.0% | Sold out |